Profile data is unavailable for this security.
About the company
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
- Revenue in USD (TTM)0.00
- Net income in USD-151.76m
- Incorporated2017
- Employees55.00
- LocationAkero Therapeutics Inc601 Gateway Boulevard, Suite 350SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 487-6488
- Fax+1 (302) 655-5049
- Websitehttps://akerotx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | 17.45m | -135.89m | 1.40bn | 244.00 | -- | 6.43 | -- | 80.18 | -4.58 | -4.58 | 0.5939 | 5.76 | 0.0707 | -- | 1.64 | 71,504.10 | -55.09 | -31.56 | -61.63 | -33.82 | 90.87 | -- | -778.89 | -242.59 | 6.85 | -- | 0.1315 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.41bn | 642.00 | 82.05 | 3.19 | 18.37 | 2.90 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.42bn | 297.00 | 234.62 | 3.28 | 130.57 | 4.70 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -188.92m | 1.45bn | 155.00 | -- | 4.18 | -- | -- | -2.37 | -2.37 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.11 | -- | -55.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Arcus Biosciences Inc | 117.00m | -307.00m | 1.45bn | 577.00 | -- | 2.61 | -- | 12.40 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Neumora Therapeutics Inc | 0.00 | -235.93m | 1.49bn | 124.00 | -- | 3.17 | -- | -- | -2.33 | -2.33 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Xencor Inc | 168.34m | -126.09m | 1.50bn | 280.00 | -- | 2.22 | -- | 8.90 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.52bn | 124.00 | -- | 2.29 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Dynavax Technologies Corp | 232.28m | -6.39m | 1.52bn | 408.00 | -- | 2.42 | -- | 6.56 | -0.0733 | -0.0733 | 1.65 | 4.80 | 0.2343 | 0.89 | 2.50 | 569,323.50 | -0.6444 | 4.16 | -0.7216 | 5.71 | 78.40 | 64.83 | -2.75 | 9.19 | 12.96 | -- | 0.2636 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Protagonist Therapeutics Inc | 60.00m | -78.96m | 1.53bn | 112.00 | -- | 4.47 | -- | 25.47 | -1.47 | -1.47 | 1.06 | 5.83 | 0.1981 | -- | 11.56 | 535,714.30 | -26.06 | -35.90 | -28.53 | -41.36 | -- | -- | -131.59 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.53bn | 55.00 | -- | 2.30 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -38.99m | 1.53bn | 33.00 | -- | 9.24 | -- | -- | -2.97 | -2.97 | 0.00 | 4.97 | 0.00 | -- | -- | 0.00 | -37.64 | -53.90 | -41.40 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Taro Pharmaceutical Industries Ltd | 610.83m | 45.70m | 1.60bn | 1.55k | 34.94 | 0.8975 | 20.11 | 2.61 | 1.22 | 1.22 | 16.25 | 47.33 | 0.2854 | 1.45 | 2.76 | 393,068.20 | 2.14 | 1.85 | 2.59 | 2.21 | 48.02 | 56.82 | 7.48 | 6.99 | 3.03 | -- | 0.00 | 0.00 | 2.07 | -2.85 | -56.33 | -34.53 | -7.64 | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.60bn | 142.00 | -- | 3.17 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| ADMA Biologics Inc | 258.22m | -28.24m | 1.60bn | 624.00 | -- | 11.55 | -- | 6.20 | -0.1263 | -0.1263 | 1.14 | 0.5981 | 0.7621 | 1.01 | 12.03 | 413,806.10 | -8.33 | -24.80 | -9.60 | -28.00 | 34.44 | 17.02 | -10.94 | -51.31 | 1.69 | 0.924 | 0.4913 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.65bn | 1.60k | -- | 0.4724 | -- | 2.22 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
Data as of May 07 2024. Currency figures normalised to Akero Therapeutics Inc's reporting currency: US Dollar USD
49.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 5.12m | 7.43% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 4.28m | 6.21% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.77m | 5.47% |
| Alkeon Capital Management LLCas of 31 Dec 2023 | 3.76m | 5.46% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.60m | 5.22% |
| RTW Investments LPas of 31 Dec 2023 | 3.59m | 5.21% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.94m | 4.27% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 2.88m | 4.18% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 2.37m | 3.44% |
| Yiheng Capital Management LPas of 31 Dec 2023 | 1.92m | 2.79% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
